Sign In
Buy PFE
$25.69
+0.335 (+1.32%)
At Close: Jun 04, 2026
Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact
11:20am, Tuesday, 31'st Dec 2024
Sangamo Therapeutics (SGMO) shares cratered more than 50% Tuesday, a day after the biopharma firm announced that Pfizer (PFE) had pulled out of its deal to co-develop a hemophilia drug.
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
09:14am, Tuesday, 31'st Dec 2024
On Monday, Sangamo Therapeutics, Inc. SGMO regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately sever
3 Reasons to Buy Pfizer Stock Like There's No Tomorrow
07:30am, Tuesday, 31'st Dec 2024
The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents protecting their proprietary drugs expire.
Pfizer: 4 Reasons to Buy This Stock
07:28am, Tuesday, 31'st Dec 2024
Pharmaceutical giant Pfizer Inc. NYSE: PFE stock is trading back down near its pandemic lows. Every time it attempts to climb over the $30 mark, something causes shares to slide right back down.
Sangamo Therapeutics down 50% premarket on Pfizer blow
06:06am, Tuesday, 31'st Dec 2024
Shares in Sangamo Therapeutics dropped 50% premarket after Pfizer Inc (NYSE:PFE, ETR:PFE) ended its collaboration on a gene therapy for haemophilia The drug, giroctocogene fitelparvovec, met its tar
Sangamo to reclaim hemophilia A therapy rights post Pfizer termination
04:34pm, Monday, 30'th Dec 2024
Sangamo Therapeutics said on Monday it would regain full rights to its hemophilia A gene therapy after co-development partner Pfizer terminated the agreement.
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS TO REGAIN FULL RIGHTS TO HEMOPHILIA A GENE THERAPY PROGRAM FOLLOWING PFIZER'S DECISION TO CEASE DEVELOPMENT.
25 Worst Stocks to Own in January
12:21pm, Monday, 30'th Dec 2024
As President-elect Donald Trump prepares for his inauguration, his administration is gearing up to roll out significant policy shifts.
Pfizer: One Of The Next Big AI Winners
12:00pm, Monday, 30'th Dec 2024
Kirk Spano thinks Pfizer is poised to be a major AI winner, especially in cancer treatment. Potentially making it easier to manage like AIDS.
My New Year's Resolution For 2025: Invest $10,000 In These 6 Stocks
10:00am, Monday, 30'th Dec 2024
I review here the stocks of six quality companies that I am convinced will bring me closer to my ambitious goal of being able to fund my living expenses through dividends. Dividend growth investing is
5 Unbeatable Stocks I'm Eager to Buy in 2025
05:06am, Monday, 30'th Dec 2024
Investors have plenty to be thankful for in 2024. They've witnessed the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite all rocket higher by a double-digit percentage and head to multiple
My 5 Favorite Ultra-High-Yield Dividend Stocks to Buy for 2025
04:04am, Monday, 30'th Dec 2024
I like every part of the phrase "ultra-high-yield dividend stocks." Investing in stocks allows me to own portions of great businesses.
It's been an interesting year for the stock market. The broader benchmark S&P 500 (^GSPC -1.11%) blazed roughly 24.5% higher (as of Dec. 27), thanks largely to eight high-flying tech stocks with marke
Prediction: This $43 Billion Bet Will Help Pfizer Stock Take Off in 2025.
04:15am, Sunday, 29'th Dec 2024
Pfizer (PFE 0.23%) became a stock market star in early pandemic days as it brought the first coronavirus vaccine to market. The company generated billions of dollars in revenue thanks to its coronavir
Start Off the New Year With 5 Blue Chip Dividend Stocks That Pay 6% and Higher Yields
07:43am, Friday, 27'th Dec 2024
Investors love dividend stocks, especially the blue-chip variety because they offer a significant income stream and have massive total return potential.
